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Long-lasting expansion of V
 
 
 
2
 
neg
 
 
 
  
 
 T cells is a hallmark of cytomegalovirus (CMV) 
infection in kidney transplant recipients. The ligands of these cells and their role remain 
elusive. To better understand their immune function, we generated 
 
  
 
 T cell clones from 
several transplanted patients. Numerous patient V
 
 
 
1
 
 
 
, V
 
 
 
3
 
 
 
, and V
 
 
 
5
 
 
 
 
 
  
 
 T cell clones 
expressing diverse V
 
 
 
 chains, but not control V
 
 
 
9V
 
 
 
2
 
 
 
 T clones, displayed strong reactivity 
 
against CMV-infected cells, as shown by their production of tumor necrosis factor-
 
 
 
. V
 
 
 
2
 
neg
 
 
 
  
 
 T lymphocytes could also kill CMV-infected targets and limit CMV propagation in vitro. 
Their anti-CMV reactivity was specific for this virus among herpesviridae and required T cell 
receptor engagement, but did not involve major histocompatibility complex class I molecules 
or NKG2D. V
 
 
 
2
 
neg
 
 
 
  
 
 T lymphocytes expressed receptors essential for intestinal homing and 
were strongly activated by intestinal tumor, but not normal, epithelial cell lines. High 
frequencies of CMV- and tumor-specific V
 
 
 
2
 
neg
 
 
 
  
 
 T lymphocytes were found among 
patients’ 
 
  
 
 T cells. In conclusion, V
 
 
 
2
 
neg
 
 
 
  
 
 T cells may play a role in protecting against 
CMV and tumors, probably through mucosal surveillance of cellular stress, and represent a 
population that is largely functionally distinct from V
 
 
 
9V
 
 
 
2
 
 
 
 T cells.
 
Although 
 
  
 
 T cells represent a minor popula-
tion at the periphery (
 
 
 
5% of T cells), they are 
normal residents in several tissues, notably epi-
thelia where they reach 10–50% of T cells. In 
humans, 70% of 
 
  
 
 T cells in the peripheral 
blood express V
 
 
 
2 in association with V
 
 
 
9 
chains. V
 
 
 
9V
 
 
 
2 T cells recognize small non-
peptidic phosphorylated antigens derived, for 
example, from 
 
Mycobacteria
 
 (1, 2), some biphos-
phonates (3), alkylamines (4), and the association
of membrane F1-ATPase and apolipoprotein 
A-I (5). These compounds are ubiquitous com-
ponents of microorganisms, as well as of self-anti-
gens. In contrast, most tissue 
 
  
 
 T cells (located 
mainly in spleen and epithelia) use the V
 
 
 
1 
chain associated with any V
 
 
 
 chain to form 
their TCR. Their antigen specificity has been 
explored less, but their propensity toward self-
reactivity has been demonstrated, as it has been 
for V
 
 
 
9/V
 
 
 
2 T cells. MHC class I–related 
chain A (MICA; a stress-induced protein ex-
pressed on epithelial cells) and CD1c are indeed 
able to stimulate V
 
 
 
1
 
 
 
 
 
  
 
 T cell lines and to in-
teract with their V
 
 
 
1 TCR (6, 7). An important 
feature of 
 
  
 
 T cells is that they do not require 
classical MHC-presenting molecules in the anti-
gen recognition process.
It is now accepted that 
 
  
 
 T cells play spe-
cific and nonredundant functions with those of 
 
  
 
 T cells, but the exact role and features of 
these cells are still a matter of debate (for re-
view see reference 8). The antigenic specificity 
and tissue distribution of 
 
  
 
 T cells make them 
important effectors of antitumor immunity. 
V
 
 
 
9V
 
 
 
2 T cells can kill myeloma and lym-
phoma cell lines in vitro (9) and injection of 
their cognate ligands was associated with im-
provement in patients with non-Hodgkin lym-
phoma or multiple myeloma (10). V
 
 
 
1 
 
  
 
 T 
 
F. Halary and V. Pitard contributed equally to this work.
 
The online version of this article contains supplemental material.
 
CORRESPONDENCE
 
 
 
 
 
Julie Déchanet-Merville: 
 
 
 
julie.dechanet@u-bordeaux2.fr
 
Abbreviations used: FSF, fore
 
-
 
skin fibroblast; MFI, mean fluo
 
-
 
rescence intensity; MICA, 
 
MHC class I–related chain A, 
 
MOI, multiplicity of infection; 
 
TAP, transport-associated pro
 
-
 
tein; TECK, thymus-expressed 
 
chemokine; ULBP, UL16-
 
 
 
binding protein; VZV, varicella 
 
zoster virus. 
ANTI-CMV REACTIVITY OF V
 
 
 
2
 
neg
 
 
 
  
 
 T CELLS | Halary et al.
 
1568
 
cells are found expanded in epithelial tumors, and they exert
 
 
an in vitro antitumor activity by recognizing antigens that are 
overexpressed on tumor cells (11, 12). In addition, the im-
portance of 
 
  
 
 T cells has been suspected in several antiinfec-
tious immune responses essentially on the basis of the selec-
tive expansion of these cells in the peripheral blood of 
patients. As far as is concerned in viral infections, increase of 
 
  
 
 T cells at the periphery has been documented in HIV 
(13), EBV (14), and HSV (15) infections. Although the re-
sults gathered so far suggest their participation in these con-
texts, their protective functions remain to be ascertained yet.
A few years ago, we demonstrated the involvement of 
 
  
 
T cells in human CMV infection. CMV is a widespread  
herpesvirus that infects 60–100% of the populations around 
the world and induces lifelong viral persistence without de-
tectable symptoms in immunocompetent individuals. In con-
trast, CMV infection in immunocompromised patients usually 
leads to severe disease. Consequently, numerous studies have 
been devoted to the understanding of the mechanisms evolved 
by the immune system to control this pathogen. CD8     cy-
totoxic T cells are usually considered as the principal actors of 
the anti-CMV cellular immune response, as they can kill 
CMV-infected cells in vitro, and adoptive transfer of CMV-
specific CD8  T cells efficiently restricts CMV infection in re-
cipients of allogeneic bone marrow (16). The marked increase 
of circulating    T cells (from  5 up to 50% of total T cells) 
we reported in kidney-transplanted patients with active CMV 
infection (17) strongly indicates an involvement of    T cells 
in anti-CMV immune responses. This cellular amplification 
occurred concomitant to the resolution of viremia, suggesting 
a protective antiviral role for    T cells (18). Interestingly, 
V 1, V 3 as well as V 5-expressing    T cells were involved, 
whereas V 9V 2 T cells never expanded, and they display a 
restricted repertoire evocative of an antigenic selection in vivo 
(17). More recent studies describe an increase of    T cell 
number in the salivary glands of infected mice (19) and dem-
onstrate a protective role for liver V 1     T cells against mu-
rine CMV by depleting    T cells in vivo (20). These data 
lend further support to the conclusion drawn from CMV-
infected patients whereby V 2neg    T cell subsets most likely 
expand or are redistributed from the tissues where they reside 
normally and which are preferential sites of CMV multiplica-
tion (e.g., intestinal epithelia, liver, or salivary glands).
The goal of the present study is to define the immune 
functions of these    T cell subpopulations in the response 
of the host to human CMV. In vitro studies were performed 
to characterize their reactivity toward CMV-infected cells 
and ultimately led us to show their reactivity against tumor 
epithelial cells.
RESULTS
V 2neg    T cells specifically recognize   
CMV-infected fibroblasts
To determine whether the V 2neg    T cells expanded in 
the context of CMV infection were able to recognize CMV-
infected cells, we have sorted these populations from the pe-
ripheral blood of different renal- or lung-transplanted pa-
tients with a CMV infection and derived cell lines under 
polyclonal stimulation (in the absence of CMV) before clon-
ing by limiting dilution. These V 2neg    T cell clones were 
seeded onto monolayers of the MRC5 fibroblastic cell line, 
which were previously infected or not with CMV for differ-
ent periods of time. Several V 2neg    T cell clones were 
found to produce high amounts of TNF  in culture super-
natants when cocultured with MRC5 monolayers previ-
Figure 1. V 2neg    T cells produce TNF  when cocultured with 
CMV-infected MRC5 cells. (A) MRC5 cells were infected for 1–4 d with 
CMV or left uninfected, and cocultured with two representative V 2neg    
T clones (5–4 and 4–29) or medium alone for TNF  release quantification 
by ELISA. Results are presented as mean  SD of culture triplicates. 
(B) V 2neg    T cells were cultured in medium alone, with PMA and ionomycin, 
or with uninfected or CMV-infected MRC5 cells. Cells were labeled with 
anti-C  mAb and anti-TNF  mAb and analyzed by flow cytometry. Only 
   T cells are shown in the histograms and the percentages of TNF -
expressing cells are indicated. (C) Anti-CMV reactive 5-4 and 4–29 clones 
have been cultured for 4 h in medium alone, with PMA and ionomycin, or 
on MRC5 cells uninfected or infected with TB40/E, AD169, or Towne 
strains of CMV, or with clinical isolates of VZV or HSV-1. Results are
mean   SD of TNF  secreted in supernatant of culture triplicates. All
results are representative of at least three independent experiments.  JEM VOL. 201, May 16, 2005 1569
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ously infected for 4 d with CMV (Fig. 1 A). Neither in-
fected MRC5 alone, nor    T cells cultured with uninfected 
MRC5 produced TNF . That TNF  produced in cocul-
ture supernatants originated from    T cells themselves was 
indicated by intracytoplasmic staining of this cytokine, 
which was only positive in V 2neg    T cell clones incubated 
on MRC5 cells infected with CMV or treated with PMA 
and ionomycin, but not when cultured with uninfected fi-
broblastic cells (Fig. 1 B). U373 (an astrocytoma cell line) 
and primary cultures of foreskin fibroblasts (FSFs) were also 
able to stimulate V 2neg    T cells after infection with CMV 
(unpublished data). CMV-reactive V 2neg    T cell clones 
expressed diverse    TCR chain associations comprising 
V 2,3, V 4, V 8, or V 9 chains associated with V 1, V 3, 
or V 5 chains (Table I). In contrast, CMV-infected MRC5 
cells were always found unable to activate control V 9V 2 
T cell clones (Table I). Reactivity of V 2neg    T cells was 
specifically directed toward CMV because they did not pro-
duce TNF  when challenged with HSV or varicella-zoster 
virus (VZV)-infected cells (Fig. 1 C), whereas MRC5 in-
fected with any of the CMV strains tested, either clinical 
(TB40/E) or laboratory adapted (AD169 and Towne), in-
duced the production of TNF  by V 2neg    T cells.
V 2neg    T cells are able to kill CMV-infected cells and to 
inhibit CMV propagation in vitro
To gain insight into mechanisms of    T cell antiviral re-
sponse, next we examined their ability to lyse CMV-infected 
cells. V 2neg    T cell clones were cultured for 4 h with 
CMV-infected or uninfected FSFs labeled with 51Cr. CMV-
infected FSFs were efficiently lysed by V 2neg     T cell 
clones (Fig. 2 A), whereas we observed no specific cytotox-
icity against uninfected FSFs.    T cells were previously 
shown to kill their targets using either the granzyme/per-
forin system, or TNF - and FasL-mediated pathways (21). 
Most cells within V 2neg    T cell clones were found to ex-
press spontaneously high levels of granzyme B and perforin 
(unpublished data). In addition, lysis of CMV-infected fibro-
blasts was not inhibited by blocking mAbs directed against 
Fas or TNF- , whereas these mAbs efficiently abrogated 
Faspos Jurkat cell lysis by Fas-Lpos 1A12 cells and the TNF -
induced lysis of WEHI cells, respectively (Fig. 2 B). More-
over, pretreatment of V 2neg    T cells with strontium ions, 
which induce exhaustive granule secretion and render per-
forin and granzyme-secreting T cells temporarily incapable 
of killing target cells, inhibited their cytotoxic activity to-
ward HT29 and CMV-infected FSFs (Fig. 2 B). These re-
sults indicate that perforin–granzyme B is the main effector 
pathway used by cytotoxic CMV-reactive V 2neg    T cells.
To assess whether V 2neg    T cells could display a by-
stander cytolytic activity toward neighboring uninfected cells 
within CMV-infected tissue, a mixture of 51Cr-labeled unin-
fected FSFs and cold CMV-infected FSFs (or vice versa) 
were incubated with V 2neg    T clones. Chromium release 
could be observed only in conditions where CMV-infected 
FSFs, but not uninfected FSFs, were labeled with 51Cr, dem-
onstrating the high specificity and direct contact requirement 
of V 2neg    T cell killing activity (Fig. 2 C).
We next asked whether the effector functions of V 2neg   
T cells could limit CMV propagation in vitro. Fibroblast 
monolayers were incubated with CMV for 2 h, washed, and 
further cultured in the presence of CMV-reactive V 2neg    T 
cell clones. After 4 d, the number of infectious particles re-
leased into the supernatant were greatly reduced in the pres-
ence of the anti-CMV V 2neg    T cell clone as compared 
with medium alone and to unrelated V 1pos or V 9V 2 T cell 
clones (Fig. 2 D). The antiviral action of 5   104 V 2neg    T 
cell clones was as potent as that of 1 U/ml IFN  used as a pos-
itive control for the inhibition of viral replication. Accordingly, 
the production of IFN  by V 2neg    T cells could explain the 
inhibition of CMV replication because an anti-IFN  blocking 
mAb nearly completely abrogated the antiviral effect of the 
V 2neg    T cells (Fig. 2 D). Thus, the recognition of infected 
MRC5 by V 2neg    T cells resulted in production of IFN  in 
sufficient amount to control CMV replication in vitro.
Recognition of CMV-infected cells by V 2neg    T cells is 
mediated through the    TCR independently of   
MHC class I presentation
To assess whether activation of V 2neg    T cells by CMV-
infected cells is mediated by antigen/TCR recognition, co-
cultures of T cell clones on CMV-infected or uninfected FSF 
monolayers were performed in the presence of increasing 
doses of anti-CD3 (OKT3) or anti-C  blocking mAbs to 
Table I.  Anti-CMV reactivity of V 2neg    T cell clones is 
independent of the TCR V chain usage
TNF  production (pg/ml)c
Patient-clone  
numbera
V segment
usageb Medium PMA   iono MRC5 MRC5   CMV
1-12 V 2,3 V 1       20 462  5   63
2-6 V 2,3 V 1  5 232           12   81
3-1 V 2,3 V 1  5 470  5   94
4-7 V 4 V 5  5 208  5 117
4-9 V 4 V 5  5   84  5 114
4-29 V 4 V 5  5 169  5 508
5-4 V 9 V 1  5 233  5 373
6-1 V 8 V 1  5 273  5   46
7-2 V 2,3 V 3  5   59  5   32
TH1 V 9 V 2  5 335  5      5
G12 V 9 V 2  5 425  5      5
  aV 2neg    T cell clones were generated from seven different patients (1–7). Two 
control V 9V 2 T cell clones were also tested (TH1 and G12).
  bV regions were identified by flow cytometry analysis using specific mAbs. V 2 and 
V 3 regions cannot be distinguished because they are recognized by the same anti-
body. V -J  sequences of all these clones are presented in Table S1 (available at http:
//www.jem.org/cgi/content/full/jem.20041851/DC1).
  c3   104 cells/well of each    T cell clone were cultured for 4 h in medium alone, or 
with PMA and ionomycin, or with MRC5 cells uninfected or infected for 4 d with 
CMV. TNF  concentration was measured in culture supernatants by ELISA. Results 
are the mean of cultures triplicates and SD was always  15% of the mean value 
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prevent TCR engagement. Addition of these mAbs inhibited 
the release of TNF  by T cells in a dose-dependent manner 
(Fig. 3 A). The slight increase of TNF  release observed with 
nonsaturating doses of the mAbs in cocultures performed 
with uninfected FSFs is likely to be related to mAb binding 
on FcR faintly expressed on FSFs and to the subsequent trig-
gering of    TCR signaling. To further establish this   
TCR involvement, we monitored the TCR down-modula-
tion at the surface of V 2neg    T cell clones after TCR en-
gagement by cognate ligand (22). An anti-CMV V 2neg and a 
control V 9V 2 T cell clone were incubated with uninfected 
or CMV-infected MRC5 cells and their TCR expression 
was measured by flow cytometry every 2 h. CMV-infected 
MRC5 cells, but not uninfected cells, strongly down-modu-
lated TCR expression only on the surface of the anti-CMV 
   T cell clone; those cells do this to an extent comparable to 
that induced by an agonistic anti-CD3 mAb (UCHT1).
We investigated next whether the interaction of V 2neg
   TCR with CMV-infected cells required antigenic presen-
tation by MHC class I molecules, which have been shown to 
be dispensable for cognate ligand recognition by    TCR 
(8). For this purpose, we used an SV40-transformed fibro-
blastic cell line (BRE-169) genetically deficient for the trans-
port-associated protein-1 (TAP-1), a peptide transporter that 
is critical for peptide loading on and subsequent surface ex-
pression of MHC class I molecules (23). Preliminary experi-
ments demonstrated that this cell line was permissive for 
CMV infection (unpublished data). Despite their lack of 
MHC class I expression, 4 d after their infection with CMV, 
BRE-169 cells were as potent as MRC5 in triggering the 
production of TNF  by V 2neg    T cells (Fig. 3 C). As with 
MRC5, no activation of    T cell clones was observed when 
BRE cells were incubated with heat-inactivated CMV.
V 2neg and V 2pos    T cells express different patterns of 
homing receptors
V 2neg    T cells are thought to be mainly located within tis-
sues under physiological conditions, and their expansion ob-
served in the peripheral blood of transplanted patients during 
CMV infection could be a consequence of their vigorous ac-
Figure 2. V 2neg    T cells can lyse CMV-infected cells and limit 
CMV replication in vitro. (A) FSF uninfected (dashed lines) or infected 
with CMV (solid lines) were labeled with 51Cr and incubated with four dif-
ferent anti-CMV    T cell clones. Results are the mean of specific lysis of 
culture triplicates. SD was always  15% of the mean value (not depicted). 
(B) As in A, but blocking mAbs directed against TNF  (20  g/ml) or Fas 
(1  g/ml) or 20  g/ml control mAb were added at the start of cell contact. 
When indicated,    T cell clone was pretreated with SrCl or NaCl at 
20 mM before contact with FSF. Viability of T cells after this treatment 
was  90%. Effector/target ratio was 10/1. As positive control for mAb 
efficacy, WEHI or Jurkat cells were labeled with 51Cr and incubated with 
50 pg/ml TNF  or Fas-L  1A12 cells (10/1 effector/target ratio), respec-
tively. Same results were obtained with the 5–4 clone. (C) Uninfected or 
infected FSF were labeled as in A and mixed with the same number of 
either cold uninfected FSF or cold infected FSF, and incubated with the 
4–29 anti-CMV    T cell clone at a 10/1 effector/target ratio. (D) FSF 
were incubated for 2 h with CMV, washed, and incubated in medium 
alone, with IFN  (100, 10, and 1 U/ml), or with the anti-CMV 4-29 or unre-
lated T clones (V 1 or a V 9V 2 T cells). Anti-IFN  blocking mAb or an 
unrelated control mAb (20 and 2  g/ml) were added to 4-29 T cell cocul-
tures. After 4 d, infectious CMV was titered in culture supernatants by 
plaque assay on MRC5 cells. Results are mean   SD of culture triplicates 
and are representative of three independent experiments.  JEM VOL. 201, May 16, 2005 1571
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tivation in infected sites. Identification of these tissues would 
be instrumental to further understanding the antiviral func-
tions of V 2    T cells, but obvious ethical reasons limit in 
situ studies in transplanted patients. Hence, we determined 
the pattern of expression of homing receptors by V 2pos and 
V 2neg    T cells through ex vivo staining of circulating 
lymphocytes from 10 CMV-infected transplanted patients. 
CCR5,  4 7 integrin, CXCR4, CCR6, and to a lesser ex-
tent CXCR3 and CCR9 were expressed on variable fractions 
of V 2pos    T cells (Fig. 4 A). In contrast, V 2neg    T cells 
were negative for 8 out of the 10 chemokine receptors tested. 
Only CXCR4 and intestinal homing receptor  4 7 integrin 
expression were detected in a significant fraction of cells in a 
majority of patients. Interestingly, expression of CCR9, the 
receptor for thymus-expressed chemokine (TECK)/CCL25 
and marker of small intestine homing capacity of lymphocytes 
(24), was found in a fraction of cells ranging from 11 to 30% 
in six patients. Of note, a population of CCR9high V 2neg   
T cells was clearly identified in some patients (unpublished 
data). Thus, although chemokine receptor expression by 
V 2neg    T cells was limited to CXCR4 and CCR9, that of 
V 2pos    T cells was much more diverse with especially high 
percentages of CCR5 positive cells. Expression of CCR9 and 
 7 integrin was also found on the V 2neg    T cell clones dis-
playing a reactivity against CMV-infected fibroblasts (Fig. 4 
B). CCR9 expression on 5–4 and 4–13 clones was weak, but 
sufficient to transduce a signal because incubation of these 
clones with TECK/CCL25 induced cytoskeleton reorganiza-
tion as detected by F-actin polymerization assay (Fig. 4 C). 
All these findings suggest an Ag-driven expansion of V 2neg
   T cells within intestinal mucosa, which is also a frequent 
site of CMV multiplication (25), before their passage in the 
periphery.
Figure 3. V 2neg    TCR recognition of CMV-infected cells is TCR 
dependent but MHC class I independent. (A) FSF were infected or not 
with CMV and incubated with the 4–29 anti-CMV V 2neg    T cell clone in 
the presence or absence of increasing doses of anti-CD3 or anti-C  blocking 
mAbs or control mAb (ctl). Results are mean   SD of TNF  secretion in culture 
duplicates and are representative of three independent experiments alter-
natively performed with the 4–29 or 5–4 clone. (B) MRC5 cells were in-
fected (open triangles) or not (closed squares) with CMV and incubated with 
an anti-CMV 4-29 or a V 9V 2 T cell clone. T cells alone were also incu-
bated with an agonistic anti-CD3 mAb (10  g/ml, UCHT1, closed circles). 
Every 2 h, cells were harvested and stained with an anti-C  mAb. Results are 
presented as the MFI of cells and are representative of two independent 
experiments. (C) CMV-reactive 4-29 clone was cultured on MRC5 or TAP-
deficient BRE cells either uninfected (white bars) or infected with intact 
(gray bars) or heat-inactivated CMV (black bars). Results are mean   SD of 
TNF  secretion in culture triplicates and are representative of three inde-
pendent experiments performed with 4–29 or 5–4 clones.
Figure 4. Pattern of chemokine and homing receptor expression by 
V 2neg and V 2pos T cells. (A) PBMCs from 10 CMV-infected transplanted 
patients were labeled with an anti-C  mAb, an anti-V 2 mAb, and each 
specific mAb directed against chemokine or homing receptors, before 
being analyzed by flow cytometry. For one patient, the percentage of 
positive cells for each receptor was evaluated among both V 2neg    T 
cells and V 2pos    T cells. Results are presented as the percentage of 
positive cells in each patient depicted by a specific symbol. The mean 
expression for each receptor appears as a short line. (B) Three different 
CMV-specific V 2neg    T cell clones were stained with anti– 7-integrin 
or anti-CCR9 mAbs (thin line) or with a control mAb (bold line), and 
analyzed by flow cytometry. (C) Polymerization of F-actin in response to 
TECK/CCL25 was tested on two V 2neg    T clones by flow cytometry as 
described in Materials and methods.ANTI-CMV REACTIVITY OF V 2neg    T CELLS | Halary et al. 1572
Anti–CMV-reactive V 2neg    T cells also recognize 
intestinal tumor epithelial cells
The aforementioned results were consistent with the well-
established association of V 1    T cells with intestinal epi-
thelia (26). These cells have been studied particularly for 
their increased frequencies in various epithelial tumors (11, 
27) and their ability in vitro to kill tumor intestinal epithelial 
cells (6). Because one hallmark of    T cells is their recogni-
tion of broadly distributed antigens (8), we tested whether 
these cells could recognize both CMV-infected cells and tu-
mor intestinal epithelial cell lines. As shown in Fig. 5 and 
Table II, anti-CMV V 2neg    T cell clones were strongly 
activated when cocultured with the colon tumor epithelial 
cell lines Caco2 and HT29. Latent CMV infection of these 
cell lines was ruled out as CMV DNA could not be detected 
by PCR (unpublished data). Under these culture conditions, 
V 2neg    T cells produced TNF  and IFN  (Fig. 5 A), and 
displayed a FasL-, TNF -independent and perforin-depen-
dent cytotoxic activity toward the target cells (Fig. 5 B). In 
contrast, V 2neg    T cell clones did not respond to other 
transformed cell lines from diverse origins (i.e., Daudi [Bur-
kitt EBV] or THP1 [monocytoid leukemia]; Fig. 5 A). All 
anti-CMV V 2neg    T cell clones tested that express dis-
tinct V  or V  chains, but not V 9V 2 T cell clones, were 
stimulated by HT29 (Fig. 5 C). This stimulating effect in-
creased with the number of HT29 cells added in the co-
culture and was prevented by semi-permeable membrane 
separation between HT29 and T cells (Fig. S1, A and 
B, available at http://www.jem.org/cgi/content/full/
jem.20041851/DC1). As with CMV-infected cells, the 
V 2neg    T cell response evoked by HT29 involved TCR 
engagement because it was associated with a down-modula-
tion of TCR surface expression (Fig. 5 D) and was abrogated 
by an anti-CD3 or anti-C –blocking mAbs (Fig. S1 C). To 
test if this reactivity was an attribute of transformed epithelial 
cells, the activation of V 2neg    T cells by tumor versus 
normal epithelial cells was compared. As shown in Fig. 5 E, 
normal epithelial cells isolated from fetal colon (FHC) or 
Figure 5. Anti–CMV-reactive V 2neg    T cells are also reactive 
against intestinal tumor epithelial cells. (A) V 2neg    T cell clones 
were cultured in medium alone, with U373 cells uninfected or infected 
with CMV, with PMA and ionomycin, with HT29 or Caco2 monolayers, or 
with Daudi or THP-1 cells. All cells were harvested, permeabilized, and 
labeled with anti-IFN  and anti-TNF  mAbs. Percentages correspond to 
cells that expressed TNF  and/or IFN . Results shown are representative 
of experiments performed with four different clones. (B) As in Fig. 2 B 
with HT29 cells instead of FSF. The same results were obtained with the 
5–4 clone. (C) Two V 2neg    clones (4–29 and 5–4) or one control 
V 9V 2 T cell clone were incubated in medium alone (white bars), on 
HT29 cells (gray bars), or with PMA and ionomycin (black bars). (D) The 
4–29 anti-CMV    T cell clone was incubated in medium alone, with an 
agonistic anti-CD3 mAb (10  g/ml, UCHT1) or with HT29 cells. At indicated 
times, cells were harvested and stained with an anti-C  mAb. Results are 
presented as the MFI   SD of culture triplicates and are representative of 
two independent experiments. (E) The 4–29 T cell clone was cultured in 
medium alone, with PMA and ionomycin or on normal (HIEC and FHC) or 
tumor (HeLa, HT29, CaCo-2) intestinal epithelial cell lines. Epithelial 
cells were also cultured in medium alone. After 6 h of incubation, TNF  
secretion was quantified in culture supernatant.  JEM VOL. 201, May 16, 2005 1573
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small intestine (HIEC) clearly failed to stimulate TNF  se-
cretion by V 2neg    T cells in sharp contrast with their tu-
moral counterparts HT29, CaCo2, or HeLa tumor cells. 
The latter data strongly suggested that V 2neg    T cells rec-
ognized a self-antigen whose expression on target cells is ei-
ther linked to CMV infection or malignant transformation.
Recognition by V 2neg    T cells of CMV-infected cells or 
tumor epithelial cell lines is not mediated by NKG2D ligands
V 1    T cells isolated from epithelial tumors have been 
shown to recognize the stress protein MICA, which is over-
expressed on the surface of tumor epithelial cells (11). The 
receptor for this molecule on intraepithelial lymphocytes is 
NKG2D, which also interacts with UL16-binding proteins 
(ULBP1, 2, and 3). We thus wondered whether MICA/B 
or ULBP could be ligands for the CMV- and epithelial cell–
reactive V 2neg    T cells through recognition of NKG2D 
that we found constantly expressed on V 2neg    T cells 
(unpublished data). An anti-NKG2D–blocking mAb or the 
NKG2D-Fc molecule added to cocultures of V 2neg    T 
cell clones, along with HT29 tumor cells or CMV-infected 
MRC5 cells, did not affect target cell killing (Fig. 6), while 
significantly decreasing lysis of MICA  K562 cells by 
NKG2D  NKL; inhibition of NKL-mediated K562 lysis 
was partial probably because other NKRs than NKG2D 
might be involved in activation of NKL cytotoxicity by 
K562. To confirm the aforementioned results, several epi-
thelial tumor cell lines differing by their expression level of 
NKG2D ligands were tested for their ability to activate 
V 2neg    T cell clones: HeLa (cervical carcinoma); HT29, 
CaCo2, and SK-CO1 (all colon adenocarcinoma); HUTU-80
(duodenal carcinoma); SK-MES (lung carcinoma); HUH-7 
(hepatocellular carcinoma); and CMV-infected FSFs. All 
cells were negative for ULBP1, positive for ULBP2 except 
CMV-infected FSFs, negative for ULBP3 except HT29 
cells, and positive for MICA except HUH-7, SK-CO1, and 
CMV-infected FSFs (Fig. S2, available at http://www. 
jem.org/cgi/content/full/jem.20041851/DC1). Two MICA,
ULBP1, 3-negative epithelial cell lines (SK-CO1 and HUH-7)
stimulated at least two of the five V 2neg    T cell clones 
tested (Table II). Moreover, whereas all clones tested pro-
duced TNF  when cultured with HT29, most of them were 
not stimulated when cultured with HUTU-80 or SK-MES 
that clearly expressed MICA and ULBP2. Finally, CMV-
infected FSFs did not express any of the NKG2D ligands 
tested, whereas they activated V 2neg    T cell clones well 
(Table I). These results established that NKG2D ligands 
were neither necessary, nor sufficient to activate anti-CMV 
V 2neg    T cells, and they support our hypothesis that alter-
native recognition processes of epithelial tumors by V 1 T 
cells must exist (11).
High frequency of CMV- and tumor epithelial cell-reactive 
V 2neg    T cells among patients’    T cells
To analyze the frequency of V 2neg     T cells reactive 
against tumor and CMV-infected cells among peripheral T 
cells of CMV-infected transplanted patients, polyclonal    T 
cell lines from five CMV-infected transplanted patients were 
generated with PHA, IL-2, and allogeneic PBMCs. Such 
Table II.  Reactivity of V 2neg    T cells against tumor epithelial cells is independent of MICA expression 
 TNF  production (pg/ml)a
 MICAneg cell lines MICApos cell lines
Clones  V segment usage SK-CO1 HUH-7 HUTU-80 SK-MES HeLa HT-29 Caco-2
2-6  V 2,3 V 1  5           70 414         7   40   98 103
4-13 V 4 V 5  5  5      5  5   15 220 333
4-29 V 4 V 5   70           91      5  5 281 546 615
5-4 V 9 V 1 105           34   30  5 388 428 543
5-15 V 8 V 1     8 109 324 223 344   54   36
  a3   104 cells/well of five different V 2neg    T cell clones were cultured for 4 h on monolayers of seven tumor epithelial cell lines expressing MICA or not. TNF  concentration 
was measured in culture supernatant by ELISA. Results are the mean of culture triplicates and SD was always  15% of the mean value (unpublished data).
Figure 6. NKG2D is not involved in the activation of V 2neg    T 
cells by CMV-infected fibroblasts or HT29. V 2neg    T cell clones were 
incubated with 51Cr-labeled CMV-infected or uninfected FSF or HT29, in 
medium alone or with a control or a blocking anti-NKG2D mAb (20  g/ml), 
or with the NKG2D-Fc or control ICAM2-Fc chimeric molecules (both at 20 
 g/ml). Effector/target ratio was 10/1. As positive control of blocking 
reagent efficiency, 51Cr-labeled MICA  K562 cells were incubated with 
NKG2D  NKL cells at a 10/1 effector/target ratio. Results are expressed as 
mean   SD of specific lysis in culture triplicates and are representative of 
three independent experiments performed with 4–29 and 5–4 T cell clones.ANTI-CMV REACTIVITY OF V 2neg    T CELLS | Halary et al. 1574
polyclonal activation has previously been shown to maintain 
the initial repertoire of T cells (28). The reactivity of these 
polyclonal    T cell lines against HT29 or CMV-infected 
FSFs was quantified by detecting the induced expression of 
membrane CD107a, a highly sensitive marker of cytotoxic 
activity (29). When incubated for 6 h on HT29 or CMV-
infected FSF monolayers, a considerable proportion of V 2neg
   T cells within the polyclonal cell lines displayed a specific 
cytolytic activity as evidenced by their strong CD107a sur-
face expression (Fig. 7). Uninfected FSFs only induced a 
minimal expression of CD107a on T cells. Of note, the 
V 2pos T cells contained in the cell lines did not express 
CD107a in the presence of HT29 or CMV-infected FSFs, 
highlighting the discrete specificity of V 2neg T cell activa-
tion. The mean   SD percentages of CMV/HT29-reactive 
V 2neg    T cells for the five tested patients were 16.9  
13.1% and 11.3   13.7%, respectively (Fig. 7 B, top). For 
comparison, the frequency of these cells in a naive CMV 
repertoire of    T cells was studied in blood donors with a 
negative serology for CMV. The low number of V 1pos and 
V 3pos    T cells present in the peripheral blood of donors 
were sorted from 108 PBMCs and expanded in the same 
conditions as described previously for obtaining patients’ 
V 2neg polyclonal cell lines. As shown in Fig. 7 B (bottom), 
CMV/HT29-reactive V 2neg    T cells were virtually ab-
sent from the three CMV seronegative blood donors ana-
lyzed (mean   SD of CD107apos cells: 2.1   1.8% and 2.1  
1.6%, respectively). These results establish the in vivo rele-
vance of the V 2neg    T cell reactivity against CMV and tu-
mor cells, and the important selection of these cells under vi-
ral pressure in allograft recipients.
DISCUSSION
Because the knowledge on the functions, antigenic specific-
ity, and precise localization of V 2neg    T cells is currently 
limited, the marked expansion of these cells in the peripheral 
blood of transplant patients undergoing active CMV infec-
tion provides a unique opportunity to examine their role 
within the immune system.
In this study, we showed that fibroblasts infected with 
CMV triggered the production of large amounts of TNF 
by V 2neg    T cells through a mechanism involving TCR 
engagement but not MHC presentation. In contrast, we 
could never observe activation of V 9V 2 T cells in the 
presence of CMV-infected cells. This result agrees with the 
absence of V 9V 2 T cell expansion in the peripheral blood 
of patients suffering from CMV infection (17). Anti–CMV-
reactive V 2neg    T cell clones expressed diverse V  or V 
chains, such as MIC and CD1c-specific V 1 T cells, which 
express diverse V  chains and nevertheless recognize the 
same antigen (6, 7). Together, these observations suggest 
common functions for different subsets of the V 2neg    T 
cell population (V 1, V 3, V 5) that clearly differ from that 
of V 9V 2 T cells.
V 1 T cells are the main subset of    T cells found in tis-
sues, particularly in epithelial tissue and spleen. The localiza-
tion of other V 2neg    T cell subsets remains more elusive 
and they are virtually undetectable in the peripheral blood 
Figure 7. Anti-CMV and antitumor reactivity of polyclonal    T 
cell lines isolated from CMV  transplanted patients and CMV  
blood donors. Polyclonal    T cell lines were generated from five differ-
ent CMV-infected transplanted patients (TP 1–5) and polyclonal V 2neg    
T cell lines were generated from three different blood donors (BD 1–3). 
These lines were incubated in medium alone or on monolayers of HT29 or 
of CMV-infected or uninfected FSF in the presence of an anti-CD107a 
mAb. After 6 h, T cells were stained with anti-C  and anti-V 2 mAbs and 
analyzed by flow cytometry. (A) Staining profiles obtained with the TP1    
T cell line. Indicated are percentages of CD107a  cells among the V 2neg 
(top left quadrant) or V 2pos (top right quadrant) populations. (B) Percent-
ages of CD107a  cells among V 2neg    T cells for each tested trans-
planted patient or blood donor.  JEM VOL. 201, May 16, 2005 1575
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under normal conditions. The observation of a major expan-
sion of rare subsets, such as V 3 or V 5 T cells, in the periph-
eral blood of CMV-infected transplant patients indicates that 
these cells probably originate from tissues, where they are ac-
tivated after CMV infection and redistributed thereafter into 
the blood. Accordingly, the only tissue-specific homing re-
ceptors significantly detected on V 2neg    T cells in the pe-
ripheral blood of CMV-infected transplant patients are  4 7 
and CCR9, two homing receptors defining gut tropism of 
effector lymphocytes, including    T cells (24, 30). Indeed, 
marked diminution of    T cells in gut epithelia has been 
found in mice lacking CCR9 (31). It is noteworthy that the 
panel of chemokine receptors expressed by V 2neg    T cells 
is much more restricted than that expressed by V 9V 2 T 
lymphocytes, underlying intestinal origin of these cells.
The antiviral activity of V 2neg    T cells, which can kill 
CMV-infected cells, is at least in part mediated by a per-
forin–granzyme-dependent lytic activity. Notably, these T 
cells also limit the propagation of CMV in cell cultures 
through their secretion of IFN , a renown inhibitor of viral 
replication (32). Because V 2neg     T cell expansion in 
transplant patients is concomitant to the resolution of CMV 
infection (18), it is tempting to speculate that their ability to 
kill CMV-infected cells and to limit CMV propagation in 
vitro is probably involved in a protective antiviral response, 
although no data thus far directly supports this hypothesis in 
vivo. Because intestinal epithelium is a frequent site of CMV 
replication (25), V 2neg    T cells might well be activated 
and expand locally in contact with CMV-infected cells and 
participate to an efficient, coordinated mucosal host defense. 
This assumption is supported by a study performed in    T 
cell–deficient mice demonstrating a protective role of liver 
   T cells in host defense against murine CMV (20).
Homing of    T cells to mucosal effector sites has been 
related to their widely illustrated antitumoral activity in vivo 
and in vitro (9). V 1pos T cells were particularly shown to in-
filtrate carcinoma and to kill tumor epithelial cells (11, 27). 
Accordingly, we report in the present study that anti-CMV 
reactive V 2neg    T cells were activated by several epithelial 
cell lines in a TCR-dependent fashion, demonstrating an an-
tiviral and antitumor cross-reactivity of these cells. Notewor-
thy, V 2neg    T cells did not recognize normal intestinal ep-
ithelial cells, indicating their specificity toward transformed 
cells and suggesting their role in antitumor immunity, al-
though in vivo studies are required to support this hypothesis.
In agreement with the absence of V 2neg    T cell expan-
sion in transplant patients suffering from VZV, HSV, or EBV 
infections (17), no reactivity of V 2neg    T cells was ob-
served in vitro against these herpesviruses. This suggests that 
the ligand recognized by V 2neg    T cells is either a specific 
CMV structure or a cellular antigen selectively induced in 
CMV-infected cells. Self-recognition of a stress molecule is 
consistent with both previous descriptions of CD1c and MIC 
as ligands for V 1 T cell lines and the response of V 2neg   
T cells to both CMV-infected and tumor epithelial cells. 
CD1c involvement in V 2neg    T cell activation can be ex-
cluded because neither infected fibroblasts nor target epithe-
lial cell lines expressed this antigen (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20041851/DC1), which 
is exclusively found on antigen-presenting cells (7). The in-
volvement of MICA was excluded using blocking mAbs and 
showing reactivity of V 2neg    T cell clones toward CMV-
infected FSFs or some epithelial cell lines that do not express 
MICA. Conceivably, the danger signal recognized by V 2neg
   T cells may be a common self-antigen induced on epithe-
lial cell surfaces by different types of stresses, such as CMV 
infection or cell transformation. However, a molecular 
mimicry between a CMV antigen and a structure present on 
tumor epithelial cell surface cannot be excluded as CMV 
evolved with its host by incorporating numerous cellular 
genes in its own genome (33).
Co-stimulation molecules involved in anti-CMV and an-
titumor-reactive V 2neg    T cell activation are still to be 
identified. NKG2D-mediated recognition of intestinal epi-
thelial cells by intraepithelial lymphocytes has been reported 
in several previous studies (11, 34, 35). NKG2D has also been 
shown to costimulate CMV-specific CD8    T cells (36). In 
sharp contrast, cytolytic activity of V 2neg    T cells against 
CMV-infected or tumor cells did not involve NKG2D, at 
least in vitro. Nevertheless, we still cannot exclude that pri-
mary activation of naive V 2neg    T cells in vivo might re-
quire NKG2D engagement, but that subsequent induction of 
committed cell effector functions by target cells might de-
pend exclusively on TCR or on other coreceptors.
The anti-CMV and antitumor reactivity of a significant 
proportion of V 2neg    T cells within polyclonal    T cell 
lines isolated from patients highlighted the relevance of this 
population in vivo. The expansion of these cells related to an 
acute CMV infection, the association of this expansion with 
the resolution of CMV infection, and the ability of V 2neg
   T cells to kill CMV-infected cells and limit CMV repli-
cation in vitro further support a direct implication of    T 
cells in the anti-CMV immune response. Recognition of 
their ligand independent of MHC presentation (a) most 
probably make those cells suitable antiviral immune effectors 
to neutralize a pathogen such as CMV that down-modulates 
MHC class I molecule expression, and (b) encourage their 
use in the development of future immunotherapy protocols 
for CMV infections once the molecular target recognized by 
V 2neg    T cells has been identified.
MATERIALS AND METHODS
Patients. After giving their informed consent, kidney and lung allograft recip-
ients receiving standard immunosuppressive regimen were included in the 
present study approved by the local medical ethics commitee. They developed 
a CMV infection associated with an expansion of V 2neg    T cells and diag-
nosed based on CMV pp65 antigen positivity ( 1 cell per 2   105 leukocytes) 
in peripheral blood leukocytes (detection kit from Argene Biosoft). Blood sam-
ples were taken either during the CMV infection or soon after its resolution.
Antibodies (Abs) and cell lines. The following mAbs were purchased 
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(IMMU 389), anti-V 3 (P11.5B), anti-V 9 (IMMU 360), anti-V 8 
(R4.5), and anti-V 2/3/4 (23D12). Anti-V 4 mAb (94) was provided by 
M. Bonneville (INSERM U463, Nantes, France). Anti–TNF-  (Mab11), 
anti–IFN-  (25723.11), antiperforin ( G9), and anti-CD107a (H4A3) were 
purchased from BD Biosciences and anti–granzyme B (2C5) was obtained 
from Santa Cruz Biotechnology, Inc. Neutralizing anti-CD1c mAb (F10/
21A3) was provided by S. Porcelli (Yeshiva University, New York, NY). 
The anti–HLA class I mAb (W6/32) was purchased from DakoCytomation. 
The anti-IFN  (4S.B3) blocking mAb was purchased from BD Biosciences, 
the anti-TNF  (Infliximab) blocking mAb was obtained from Schering-
Plough Laboratory, the anti-NKG2D (149810) blocking mAb, the 
NKG2D-Fc, and ICAM2-Fc molecules were obtained from R&D Systems, 
and the anti-Fas (ZB4) blocking mAb was obtained from Beckman Coulter. 
The anti-MICA mAb (SR104; reference 34) was a gift from S. Caillat-
Zuckman (Hôpital Necker, Paris, France). The anti-CD3 neutralizing mAb 
(OKT3) was provided by Janssen-Cilag and the anti-CD3 (UCHT1) ago-
nist was a gift from C. Hivroz (Institut Curie, Paris, France). Anti-CCR1, 
3, 5, 6, 7, 9, and anti-CXCR3, 4, 5, 6 mAbs were obtained from R&D 
Systems; anti-CLA and anti-integrin  7 was obtained from BD Biosciences; 
and anti-integrin  4 was obtained from Beckman-Coulter. IFN  was pur-
chased from Bender MedSystem and IL2 was given by Chiron. Primary hu-
man FSFs were a gift from C. Pain (INSERM EMI0217, Bordeaux, 
France). TAP1 /  BRE-169 cells is a TAP-deficient skin fibroblast cell line 
(23) immortalized by transformation with a vector expressing SV40 T and t 
antigens and human telomerase. Normal epithelial cell lines were isolated 
from human fetal colon (FHC; no. CRL-1831; American Type Culture 
Collection) and small intestine (HIEC; reference 37) was a gift from J.F. 
Beaulieu (University of Sherbrook, Quebec, Canada). The WR19L cells 
transfected with the cDNA coding for the Fas-L (1A12 cells; reference 38) 
was a gift from S. Nagata (Osaka University Medical School, Osaka, Japan). 
All cell lines are repeatedly screened for mycoplasma contamination and 
found to be negative.
Generation of    polyclonal cell lines and clones.    T cell subpop-
ulations were sorted from patients’ or healthy donors’ PBMCs using anti-
C , anti-V 1, or anti-V 3 mAbs and magnetic beads coated with sheep 
anti–mouse Ig (Dynal). Bead-adherent cells were either seeded at 0.5 cell/
well for direct cloning or expanded in bulk cultures to generate polyclonal 
   cell lines with 1,000 U/ml rIL-2, 1  g/ml PHA-L (Sigma-Aldrich), and 
irradiated allogeneic PBMCs (35 Gy). After 14 d of culture, T cell clones or 
lines were phenotyped by immunofluorescent staining and analyzed by flow 
cytometry on a FACSCalibur apparatus (BD Biosciences) as described else-
where (17).
Infection of MRC5 and FSF. CMV suspensions were usually produced 
with the clinical strain TB40/E (a gift from C. Sinzger, University of Tu-
bingen, Tubingen, Germany) as previously described (17). When specified, 
the laboratory strains AD169 and Towne were also used. HSV and VZV 
suspensions were provided by S. Michelson (Institut Pasteur, Paris, France) 
and B.M. Imbert (CHU Nantes, Nantes, France), respectively. When nec-
essary, virus suspensions were inactivated by heating at 56 C for 30 min. 
Subconfluent monolayers of MRC5, U373, primary FSF, or TAP1 / 
BRE-169 cells were incubated with CMV suspension at a multiplicity of 
infection (MOI) of 1 for 2 h, washed, and cultured for 4 d at 37 C. Infected 
cell layers were washed before being used for coculture experiments with 
   T cell clones. Control for viral infection were performed with CMV 
(mAb E13), VZV (mAb 2013), and HSV (mAb CHA-437)-specific detec-
tion kits according to manufacturer’s instructions (Argene Biosoft).
Detection of cytokine production.    T cell clones (3   104/well) 
were incubated with monolayers of epithelial cell lines or virus-infected or 
noninfected MRC5, FSF, U373, or TAP /  BRE-169 cells for 6 h at 37 C. 
As a positive control for activation,    T cell clones were incubated with 25 
ng/ml PMA (Sigma-Aldrich) and 1  g/ml ionomycin (Sigma-Aldrich). 
TNF-  released into the supernatant was quantified by ELISA according to 
the manufacturer’s recommendations (Bender Medsystems). For intracellular 
staining of TNF  and IFN , 10  g/ml brefeldin A (Sigma-Aldrich) was 
added to the coculture for the last 5 h. Cells were harvested, washed, surface 
labeled with the anti-C  mAb, fixed with FACS lysing solution, and perme-
abilized in FACS permeabilizing solution (BD Biosciences) followed by stain-
ing with anti-TNF  and/or anti-IFN  mAbs and analysis by flow cytometry.
Cell cytotoxicity assays. Cytolytic activity of    T cells was measured by 
a standard 51Cr-release assay. In brief, epithelial cells and CMV-infected or 
noninfected fibroblasts were labeled with 51Cr (1.85 MBq/106 cells), for 1 h 
at 37 C, then 3,000 cells/well were incubated with V 2neg    T cell clones 
at the indicated effector/target ratios. In control experiments, WEHI and 
Jurkat cells were labeled with 51Cr and incubated with 50 pg/ml TNF  or 
the Fas-ligand  WR19L cells (1A12 cells), respectively. After 4 h at 37 C, 
51Cr released in supernatant was measured and the percent of specific 51Cr 
release was calculated as previously described (39). The spontaneous 51Cr re-
lease from target cells in medium alone was always  15% of the control 
maximal 51Cr release obtained with 1% Triton X-100. For degranulation ex-
periments, the effector T cells were pretreated with 20 mM strontium chlo-
ride (Sigma-Aldrich) or sodium chloride as control at 37 C overnight and 
washed, and cell viability was evaluated by eosin dye exclusion.
Cytotoxic potential of    T cell lines and clones was also measured by 
the flow cytometric CD107a assay (as described previously (29). In brief, 
6-h cocultures of    T cells with target cells were performed as for cytokine 
quantification, except that anti-CD107a mAb was added at the onset of the 
culture. Brefeldin A was added in the coculture for the last 5 h, and cells 
were harvested, surface stained with anti-C  and anti-V 2 mAbs, and ana-
lyzed by flow cytometry.
TCR down-modulation experiments. The assay for down-modulation 
of TCR–CD3 was performed as described previously (22). In brief, T cell 
clones (105 cells/well) were cultured on HT29 or MRC5 monolayers in-
fected or not with CMV, or with a soluble anti-CD3 agonist mAb at 10 
 g/ml for 0, 2, 4, and 6 h. T cells were collected, double stained with anti-
C  mAb and propidium iodide (Sigma-Aldrich), and analyzed by flow cy-
tometry. The down-modulation of TCR–CD3 complexes at T cell surfaces 
was expressed as the mean fluorescence intensity (MFI) of the TCR   
staining as a function of time.
CMV multiplication assay. Subconfluent FSF cell monolayers were cul-
tured for 2 h with a CMV suspension at a low MOI of 0.1. Cells were 
washed twice to remove free virus and cultured with    T cell clones (5  
104 cells/well in 100  l) or IFN-  at indicated concentrations. After 4 d of 
culture, infectious CMV particles released were quantified in culture super-
natants by a standard plaque assay (40).
F-actin polymerization assay. Intracellular filamentous (F)-actin poly-
merization was tested as previously described (41). In brief, T cells (8  
106/ml) were incubated at 37 C with or without 300 ng/ml TECK/
CCL25, and added at indicated times to 400  l of the assay buffer contain-
ing 4   10 7 mol/l FITC-labeled phalloidin, 0.5 mg/ml L- -lysophos-
phatidylcholine (both obtained from Sigm-Aldrich), and 4.5% formalde-
hyde in PBS. Fixed cells were analyzed by flow cytometry, and percentage 
change in MFI was determined for each sample.
Online supplemental material. Fig. S1 further details the dose-depen-
dent (SIA), contact-dependent (SIB), and TCR-dependent (SIC) activation 
of CMV-reactive    T cell clones by the HT29 cells. Fig. S2 depicts the ex-
pression of HLA-1, MICA, UCBPs, and CD1 by all target cells used in the 
present study. Table S1 displays the V -J  junctional sequences of all V 2neg
    T cell clones. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20041851/DC1.
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